Global Gestational Diabetes Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

The Global Gestational Diabetes Market has been segmented by Treatment, Type, Administration, End User, and Geography, treatment into insulin therapy, oral medication, lifestyle management, and others. Insulin therapy is the most common and effective treatment for managing gestational diabetes, especially when blood sugar levels are not controlled through diet and exercise alone. Oral medications, such as metformin and glyburide, are also used as an alternative to insulin for patients who may prefer oral treatment options, though insulin remains the standard for most cases. Lifestyle management, including dietary changes, physical activity, and weight control, is a first-line approach to managing gestational diabetes and is often combined with other treatments. The "others" category includes additional treatments like glucose monitoring and in some cases, specific supplements for managing blood sugar levels during pregnancy.

The market is also segmented by type into pre-gestational diabetes and gestational diabetes mellitus (GDM). Pre-gestational diabetes refers to women who already have diabetes before becoming pregnant, requiring more intensive management during pregnancy. Gestational diabetes mellitus (GDM) occurs when a woman develops diabetes during pregnancy and typically resolves after childbirth, though it may increase the risk of type 2 diabetes later in life. GDM is more common and is a significant focus of treatment in the gestational diabetes market. The management of GDM typically includes monitoring blood sugar levels, insulin therapy if necessary, and lifestyle changes, such as improved diet and physical activity.

The administration segment of the market includes injectable and oral administration methods. Injectable treatments, primarily insulin, are the standard for managing more severe gestational diabetes cases. Oral administration is more commonly used for women with mild gestational diabetes, as medications like metformin can be effective in managing blood sugar levels. The end-user segment includes hospitals and surgical centers, diagnostic centers, and home healthcare settings. Hospitals and surgical centers are the primary end-users for the treatment of gestational diabetes, particularly for severe cases requiring hospitalization or specialized care. Diagnostic centers play a significant role in the early detection and management of gestational diabetes, offering glucose testing and screenings for pregnant women. Home healthcare settings, including home monitoring of blood glucose levels and telemedicine consultations, are becoming increasingly popular as a way for women to manage gestational diabetes under the guidance of healthcare professionals. Geographically, North America and Europe dominate the market due to advanced healthcare infrastructure and high awareness of gestational diabetes, while the Asia-Pacific region is expected to witness significant growth, driven by rising healthcare access and increasing incidence rates of gestational diabetes.

Global Gestational Diabetes Segment Analysis

In this report, the Global Gestational Diabetes Market has been segmented by Treatment, Type, Administration, End User, and Geography.

Global Gestational Diabetes Market, Segmentation by Treatment

The Global Gestational Diabetes Market has been segmented by Treatment into Monitoring, Drug Treatment, and Non-Pharmacological Treatment.

The global gestational diabetes market is segmented by treatment into monitoring, drug treatment, and non-pharmacological treatment, each addressing different aspects of the condition. Monitoring is a crucial component of managing gestational diabetes, as it helps track blood glucose levels to ensure they remain within the recommended range. Regular monitoring allows healthcare providers to make timely adjustments to treatment plans, preventing complications for both the mother and the baby. This includes the use of home glucose meters, continuous glucose monitoring systems, and routine testing in medical settings. Monitoring helps to evaluate the effectiveness of other treatment methods and plays a key role in maintaining stable blood sugar levels throughout pregnancy.

Drug treatment is an essential part of managing gestational diabetes when lifestyle modifications alone are insufficient. The most common drug used for gestational diabetes is insulin, as it helps regulate blood sugar levels more effectively in cases where oral medications are not sufficient. In some instances, oral medications like metformin or glyburide may be prescribed to manage blood glucose levels, especially for women who have a preference for oral treatments or for those who experience challenges with insulin therapy. These drugs help to control blood sugar levels and prevent complications, though insulin therapy remains the standard for more severe cases. The use of drugs is typically combined with lifestyle interventions and monitoring to optimize control of the condition.

Non-pharmacological treatments include lifestyle management strategies such as dietary modifications, physical activity, and weight management. Women with gestational diabetes are often advised to follow a balanced, healthy diet that includes controlled carbohydrate intake to prevent blood sugar spikes. Exercise is also an important part of managing the condition, as it helps improve insulin sensitivity and regulate blood glucose levels. Non-pharmacological treatments are particularly important for women with mild gestational diabetes or those in the early stages of the condition, as these interventions can often control blood sugar levels without the need for medication. Combining non-pharmacological treatment with regular monitoring can help reduce the need for drugs, especially in cases where lifestyle changes are effective in managing the disease.

Global Gestational Diabetes Market, Segmentation by Type

The Global Gestational Diabetes Market has been segmented by Type into Type A1, Type A2, and Others.

Type A1 gestational diabetes is characterized by mild hyperglycemia during pregnancy, typically managed through lifestyle modifications such as dietary changes, physical activity, and weight management. Women with Type A1 GDM often achieve glycemic control through non-pharmacological interventions alone, with minimal risk of adverse outcomes for themselves and their babies. Type A1 GDM is commonly associated with maternal obesity, advanced maternal age, and family history of diabetes, highlighting the importance of early detection and proactive management strategies to optimize maternal and fetal health outcomes. Additionally, women with Type A1 GDM may benefit from regular monitoring of blood glucose levels, prenatal care visits, and postpartum follow-up to assess long-term metabolic health and screen for persistent hyperglycemia or type 2 diabetes.

Type A2 gestational diabetes represents a more severe form of hyperglycemia during pregnancy, requiring pharmacological interventions such as insulin therapy or oral hypoglycemic agents to achieve glycemic targets and minimize maternal and fetal complications. Women with Type A2 GDM have higher levels of insulin resistance and impaired pancreatic beta-cell function compared to those with Type A1 GDM, necessitating more intensive management approaches to control blood sugar levels and reduce the risk of adverse pregnancy outcomes. Type A2 GDM is associated with maternal obesity, gestational weight gain, and metabolic syndrome, highlighting the importance of multidisciplinary care teams and personalized treatment plans for pregnant women with complex metabolic conditions. Moreover, women with Type A2 GDM may require additional monitoring of fetal growth, amniotic fluid levels, and placental function to detect and manage potential complications such as macrosomia, polyhydramnios, and preterm birth.

Global Gestational Diabetes Market, Segmentation by Administration

The Global Gestational Diabetes Market has been segmented by Administration into Oral, Intravenous, and Others.

Oral administration represents a significant segment of the global gestational diabetes market, encompassing pharmacological interventions such as oral hypoglycemic agents and nutritional supplements delivered via the oral route. Oral hypoglycemic agents such as metformin and glyburide are commonly used in the management of gestational diabetes, providing effective glycemic control and minimizing the need for insulin therapy in some cases. These medications are typically taken orally, either as standalone treatments or in combination with lifestyle modifications such as diet and exercise to achieve target blood glucose levels. Additionally, nutritional supplements such as prenatal vitamins, folic acid, and iron supplements may be administered orally to pregnant women with GDM to support maternal and fetal health and prevent nutritional deficiencies. Oral administration offers several advantages, including ease of use, patient convenience, and non-invasiveness, making it a preferred route for delivering medications and supplements during pregnancy.

Intravenous administration represents another important segment of the global gestational diabetes market, involving the delivery of therapeutic interventions and medical treatments directly into the bloodstream via intravenous infusion. Intravenous administration may be indicated for pregnant women with severe hyperglycemia, diabetic ketoacidosis (DKA), or other acute complications of gestational diabetes requiring rapid intervention and close monitoring. Intravenous fluids, electrolytes, and insulin infusions are commonly used in the management of acute hyperglycemia and metabolic disturbances associated with GDM, providing immediate correction of fluid and electrolyte imbalances and normalization of blood sugar levels. Additionally, intravenous administration may be utilized for administering medications such as antibiotics, antihypertensive agents, and corticosteroids to pregnant women with GDM who require medical treatment for concurrent conditions or pregnancy complications. Intravenous administration offers the advantage of rapid onset of action, precise dosing control, and bypassing the gastrointestinal tract, making it an essential route for delivering critical care interventions to pregnant women with severe hyperglycemia or metabolic decompensation.

Global Gestational Diabetes Market, Segmentation by End User

The Global Gestational Diabetes Market has been segmented by End User into Hospital, and Retail Pharmacy.

The global gestational diabetes market, segmented by end-user, includes hospitals and retail pharmacies. Hospitals are a significant end-user due to the comprehensive care they offer for managing gestational diabetes, especially in cases where the condition is more severe or complicated. Hospitals provide a range of services, including diagnosis, blood glucose monitoring, insulin therapy, lifestyle management counseling, and specialist consultations. They are also equipped to handle high-risk pregnancies, offering support for both maternal and fetal health. In many cases, women with gestational diabetes are closely monitored in a hospital setting, particularly when medication adjustments or medical interventions are required.

Retail pharmacies play an essential role in the management of gestational diabetes, particularly for women diagnosed with the condition who do not require hospitalization. These pharmacies provide over-the-counter medications, such as oral diabetes medications, glucose monitoring supplies, and dietary supplements. Retail pharmacies are also a vital point of access for women seeking guidance on managing their condition with lifestyle modifications, including healthy eating and exercise. As the prevalence of gestational diabetes rises, the demand for retail pharmacy services, including blood sugar testing and patient education, is expected to grow, making pharmacies a critical resource for continuous diabetes management outside the hospital environment.

In terms of geography, hospitals dominate in regions with advanced healthcare infrastructure, such as North America and Europe, where there is a high demand for specialized medical care. Retail pharmacies, however, are expected to see significant growth in emerging markets across Asia-Pacific and Latin America, where accessibility to healthcare facilities might be limited. In these regions, retail pharmacies serve as a convenient and cost-effective option for managing gestational diabetes. Both end-users are essential in ensuring the proper management of gestational diabetes, with hospitals providing intensive care and pharmacies offering support for ongoing treatment and lifestyle management.

Global Gestational Diabetes Market, Segmentation by Geography

In this report, the Global Gestational Diabetes Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Gestational Diabetes Market Share (%), by Geographical Region, 2024

North America emerges as a significant market for gestational diabetes management, driven by factors such as high prevalence of GDM, advanced healthcare infrastructure, and strong emphasis on prenatal care and maternal-fetal medicine. The region benefits from established screening programs, clinical practice guidelines, and multidisciplinary care teams specializing in the management of GDM, promoting early detection, diagnosis, and intervention for pregnant women at risk of hyperglycemia during pregnancy. Moreover, North America boasts a robust pharmaceutical industry, research institutions, and healthcare facilities focused on advancing innovations in GDM management, including novel diagnostic tools, therapeutic interventions, and lifestyle management strategies tailored to the needs of diverse patient populations. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) play a crucial role in evaluating the safety, efficacy, and quality of GDM treatments, ensuring compliance with regulatory standards and promoting public health initiatives to reduce the burden of gestational diabetes on maternal and fetal health in North America.

Europe represents another significant market for gestational diabetes management, characterized by increasing prevalence of GDM, aging population, and rising demand for prenatal care services and maternal-fetal health programs. The region benefits from universal healthcare coverage, prenatal screening programs, and comprehensive maternity care pathways aimed at detecting and managing GDM throughout pregnancy and beyond. European countries leverage digital health technologies, telemedicine, and e-health initiatives to improve access to GDM screening, diagnosis, and management in remote and underserved areas, overcoming geographical barriers and disparities in healthcare access. Additionally, Europe fosters collaborative research networks, clinical registries, and quality improvement initiatives focused on enhancing GDM care delivery, promoting evidence-based practices, and optimizing maternal and fetal health outcomes across diverse healthcare systems and cultural contexts.

Asia Pacific emerges as a rapidly growing market for gestational diabetes management, fueled by factors such as urbanization, changing dietary habits, and increasing prevalence of metabolic disorders contributing to the rise in GDM among pregnant women in the region. The region benefits from expanding healthcare infrastructure, rising healthcare expenditures, and government-led initiatives aimed at improving maternal and child health outcomes, including GDM screening, diagnosis, and management programs. Asia Pacific countries prioritize maternal-fetal health as a public health priority, investing in prenatal care services, health education campaigns, and community outreach initiatives to raise awareness of GDM risk factors, promote healthy lifestyle behaviors, and reduce the incidence of hyperglycemia during pregnancy. Moreover, Asia Pacific fosters collaborations between public health agencies, academic institutions, and industry partners to address the unique challenges of GDM management in diverse populations, including access to healthcare, cultural beliefs, and socioeconomic disparities affecting maternal and fetal health outcomes.

This report provides an in depth analysis of various factors that impact the dynamics of Global Gestational Diabetes Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Growing Awareness and Screening Programs
• Advancements in Diagnostic Technologies
• Increasing Maternal Age and Obesity Rates

• Focus on Maternal and Fetal Health - The focus on maternal and fetal health serves as a crucial driver in addressing the challenges posed by gestational diabetes mellitus (GDM). Maternal health during pregnancy directly impacts the well-being of both the mother and the developing fetus. Gestational diabetes poses risks to maternal health, including an increased likelihood of cesarean delivery, preeclampsia, and type 2 diabetes later in life. Moreover, poorly managed GDM can lead to adverse outcomes for the fetus, such as macrosomia, birth trauma, and neonatal hypoglycemia. Therefore, there is a growing emphasis on early detection, monitoring, and management of GDM to safeguard maternal and fetal health throughout pregnancy and childbirth.

  Addressing maternal and fetal health concerns requires a multidisciplinary approach involving obstetricians, endocrinologists, dietitians, and other healthcare professionals. Collaborative care models that integrate expertise from various specialties enable comprehensive assessment, individualized treatment planning, and ongoing monitoring of maternal glycemic control and fetal well-being. This team-based approach ensures that pregnant individuals with GDM receive personalized care tailored to their unique medical history, risk factors, and preferences, thereby optimizing maternal and fetal outcomes and minimizing the risk of complications during pregnancy and childbirth.

  Advancements in prenatal care and fetal monitoring technologies contribute to the focus on maternal and fetal health in the context of gestational diabetes. Non-invasive prenatal screening tests, such as ultrasound imaging, fetal Doppler monitoring, and fetal kick counts, enable healthcare providers to assess fetal growth, development, and well-being throughout pregnancy. Additionally, continuous glucose monitoring (CGM) systems offer real-time monitoring of maternal blood glucose levels, allowing for timely adjustments to diet, exercise, and insulin therapy to maintain optimal glycemic control and minimize the risk of adverse outcomes for both the mother and the baby. By leveraging these innovative technologies and diagnostic tools, healthcare providers can prioritize maternal and fetal health in the management of gestational diabetes, ensuring the best possible outcomes for pregnant individuals and their babies.

Restraints

• Challenges in Diagnosis and Screening
• Potential Complications for Mother and Baby
• Healthcare Access and Affordability Issues

• Concerns about Overtreatment and Overdiagnosis - Concerns about overtreatment and overdiagnosis in gestational diabetes mellitus (GDM) underscore the need for judicious and evidence-based management strategies. Overtreatment refers to the unnecessary use of interventions, such as medication or insulin therapy, in individuals who may not require them based on their clinical condition or risk profile. Overdiagnosis, on the other hand, involves identifying cases of GDM that do not pose significant health risks or may resolve spontaneously without intervention. These concerns arise from variations in diagnostic criteria, differences in screening protocols, and uncertainties regarding the long-term health implications of GDM diagnosis and treatment.

  Efforts to address concerns about overtreatment and overdiagnosis in GDM focus on optimizing screening protocols, diagnostic criteria, and management algorithms to identify individuals who are most likely to benefit from intervention. This includes refining risk stratification strategies, using validated screening tools, and considering individualized risk factors such as maternal age, body mass index (BMI), and medical history. Additionally, there is a growing emphasis on shared decision-making between healthcare providers and pregnant individuals to discuss the risks and benefits of GDM diagnosis and treatment options, including the potential impact on maternal and fetal health outcomes, quality of life, and long-term health implications.

  Concerns about overtreatment and overdiagnosis in gestational diabetes mellitus (GDM) underscore the importance of adopting evidence-based practices and personalized approaches to GDM management. By optimizing screening protocols, diagnostic criteria, and treatment algorithms, healthcare providers can minimize the risk of unnecessary medical interventions, healthcare costs, and psychological distress for pregnant individuals while ensuring optimal maternal and fetal outcomes. Additionally, promoting shared decision-making and informed consent empowers pregnant individuals to actively participate in their care and make choices aligned with their values, preferences, and healthcare goals.

Opportunities

• Integration of Digital Health Solutions
• Expansion into Emerging Markets
• Research on Long-term Health Outcomes

• Collaboration with Obstetricians and Endocrinologists - Collaboration between obstetricians and endocrinologists is essential for the comprehensive management of gestational diabetes mellitus (GDM). Obstetricians play a central role in providing prenatal care, monitoring maternal and fetal health, and managing pregnancy-related complications. Endocrinologists, on the other hand, specialize in diagnosing and treating hormonal disorders, including diabetes mellitus, and possess expertise in managing glycemic control and insulin therapy. By working together, obstetricians and endocrinologists can provide integrated and coordinated care to pregnant individuals with GDM, addressing both the obstetric and metabolic aspects of their condition.

  Collaborative care models that involve obstetricians and endocrinologists facilitate early detection, diagnosis, and management of GDM, optimizing maternal and fetal outcomes. Obstetricians can screen pregnant individuals for GDM using standardized screening tests and refer those with abnormal results to endocrinologists for further evaluation and management. Endocrinologists can conduct comprehensive assessments, including glucose tolerance testing and glycemic profiling, to confirm the diagnosis of GDM and develop individualized treatment plans tailored to the patient's medical history, risk factors, and glycemic targets. This collaborative approach ensures that pregnant individuals receive timely and appropriate interventions to maintain optimal glycemic control and minimize the risk of adverse outcomes for themselves and their babies.

  Collaboration between obstetricians and endocrinologists extends beyond the management of GDM to address comorbidities, risk factors, and long-term health implications for pregnant individuals. Obstetricians and endocrinologists can work together to address lifestyle factors such as diet, exercise, and weight management that influence maternal glycemic control and pregnancy outcomes. Additionally, they can provide counseling and support to pregnant individuals regarding the importance of postpartum follow-up, ongoing monitoring of glucose tolerance, and risk reduction strategies for preventing type 2 diabetes mellitus in the future. By collaborating closely and sharing expertise, obstetricians and endocrinologists can optimize the care continuum for pregnant individuals with GDM, promoting maternal and fetal health throughout pregnancy and beyond.

Key players in Global Gestational Diabetes Market include:

• AstraZeneca
• Abbott
• Sanofi
• Biocon
• Antares Pharma
• Novartis AG

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis